Navigation Links
Co-Inventor of Amgen's Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals' First-in-Class Oxygen Enhancing Therapeutics
Date:12/21/2007

CHARLOTTESVILLE, Va., Dec. 21 /PRNewswire/ -- Diffusion Pharmaceuticals LLC, a clinical stage drug-development company commercializing first-in-class drugs utilizing a novel mechanism of action that enhances oxygen diffusion, today announced that one of its key advisors, Mr. Thomas Byrne, was recently recognized as a co-inventor of the underlying technology of Amgen's blockbuster drug Aranesp(R) (darbepoietin alpha), a erythropoiesis stimulating agent (US Patent No. 7,217,689).

Mr. Byrne, who is an Officer of Diffusion Pharmaceuticals and a member of its Board of Directors, has directed the worldwide intellectual property strategy of the Company since its inception in February 2001. His experience includes in-house counsel positions within both Genentech and Amgen.

"We are exceptionally fortunate to have such an experienced pharmaceutical development executive with scientific acumen and expertise in related intellectual property law leading our worldwide patent strategy and helping to guide the company," says David G. Kalergis, Diffusion Pharmaceuticals' Chief Executive Officer.

About Diffusion Pharmaceuticals LLC

Diffusion Pharmaceuticals LLC is a clinical-stage drug-development company commercializing a family of first-in-class drug candidates to treat serious or life-threatening medical conditions. These proprietary small molecules use a novel method of action to enhance oxygen diffusion to oxygen deprived (hypoxic) tissue. Potential clinical applications include critical care uses such as trauma, hemorrhage, stroke and heart attack, and cancer as well as chronic conditions such as cardiovascular disease, respiratory disorders, anemia and peripheral vascular disease. Enhanced diffusion of oxygen into hypoxic tissue has an important application in oncology by improving the efficacy of radiation therapy in cancerous tumors. The Company's first Phase I clinical trial for its lead molecule, trans sodium crocetinate (TSC), shows the
'/>"/>

SOURCE Diffusion Pharmaceuticals LLC
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. Novel Technology Breaks Through Cancer Pain
3. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
4. Advanced Cell Technology Announces Proposed Financing
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
10. China Technology Announces New Chief Financial Officer
11. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... -- Research and Markets  has announced the addition of the ... report to their offering. This report analyzes ... Thousands by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , ... Latin America . Annual estimates and forecasts are provided for ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 ... to raise $200,000 to fund a corporate lab ... , This development is a critical component ... of care to the implementation of personalized medicine ... of practicing medicine. , Indiegogo contributions will support ...
(Date:8/19/2014)... August 19, 2014 Robin Williams’ passing ... can take on an individual. Symptoms range from ... expression, problems swallowing and severe depression. Parkinson’s disease ... off of dopamine producing neurons of the brain. ... disease that slowly and progressively gets worse, they look ...
(Date:8/19/2014)... Research and Markets ... "Spectroscopy Equipment and Accessories - Global Strategic ... This report analyzes the ... in US$ Thousands by the following Product ... NMR-EPR Spectrometers, Near Infrared (NIR) Spectrometers, IR ...
Breaking Biology Technology:Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2
... ... software (OSS) in clinical trial electronic data capture and clinical data management. , ... Waltham, MA (PRWEB) January ... trial software, will gather on March 22nd, 2010 in Bethesda, Maryland (USA) for the ...
... ... over 24 years of experience to Professional Reprographics. , ... Irvine, California (PRWEB) January 7, 2010 -- Orange ... as President of Professional Reprographics. The naming of Cindy as President reflects Pro Repro’s ...
... , , , , SHENYANG, ... ), a leading biotechnology company focused on researching,developing, manufacturing ... it has submitted its application for a,registrational clinical trial ... Feraheme (ferumoxytol) Injection for intravenous,use. Feraheme is an intravenous ...
Cached Biology Technology:OpenClinica Global Conference to Bring Together Global Community for Open Source Clinical Trials Software 2OpenClinica Global Conference to Bring Together Global Community for Open Source Clinical Trials Software 3OpenClinica Global Conference to Bring Together Global Community for Open Source Clinical Trials Software 4Woman Owned Business President Makes Her Mark at Professional Reprographics 23SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 23SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 33SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 4
(Date:8/19/2014)... must be made to decrease China,s increasing caesarean section ... in BJOG: An International Journal of Obstetrics and ... highest caesarean delivery rates in the world. Of 16 ... caesarean. Although the exact rate is not known, the ... reports total caesarean rates ranging from 36% to 58%. ...
(Date:8/19/2014)... HOUSTON, Aug. 19, 2014 To improve students, ... poor grades, the University of Houston (UH) implemented ... for students at risk for failure. , ... Coordinating Board (THECB), the Department of Biology and ... first-year students taking "General Biology" for non-majors and ...
(Date:8/19/2014)... be used in supermarkets to encourage healthier spending habits? ... answer that very question by tracking the purchasing records ... System to rate the nutritional value of foods for ... Lab,s David Just, PhD, and Brian Wansink PhD, author ... of over 150 Hannaford Supermarkets in the Northeastern United ...
Breaking Biology News(10 mins):Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3
... advance into the vanishingly small realm of molecules and ... venerable optical microscope, after all. In fact, research at ... that a hybrid version of the optical microscope might ... 10 nanometers—a tiny fraction of the wavelength of visible ...
... simple drug, given to children with severe malaria before they ... researchers in this week's BMJ. , Every year over a ... fatalities occur outside hospital, especially in rural areas. For those ... within 24 hours of admission. , Conventional treatment, given by ...
... potential new drug that inhibits destructive cell signals that ... scientists showed they could block the growth of cultured ... , Their finding, reported in the March 22, 2005, ... is the first step toward developing a new class ...
Cached Biology News:Devising Nano Vision for an Optical Microscope 2Newly Discovered Compound Blocks Known Cancer-Causing Protein 2Newly Discovered Compound Blocks Known Cancer-Causing Protein 3
... Physical Form: buffered aqueous solution. ... terminal galactose from complex carbohydrates and glycoproteins. ... galactose under conditions where the pH must ... live cells. Unit Definition: ...
... for human cardiac troponin subunit T, a 31kDa ... for contraction of cardiac muscle. It reacts with ... cells. It also cross-reacts with human skeletal troponin ... Highly purified human cardiac troponin T ...
cystatin A (N-18)...
... to offer the ATTO-TAG series of ... primary amines. Developed by Novotny and ... reagents are similar to the important ... anthracene-2,3-dicarboxaldehyde, all of which are also ...
Biology Products: